Aviva invests in technology that detects early signs of cancer
Aviva Ventures, Aviva plc's venture capital arm, has invested in Owlstone Medical Ltd, a medical diagnostics company developing a breathalyser that can detect diseases at a very early stage.
The company is currently developing tests for lung and colorectal cancer, two of the most common terminal cancer conditions worldwide. Aviva Ventures' investment takes Owlstone Medical's total funding to $23.5 million USD (£19.3 million GBP) since its spin out of Owlstone Inc in 2016. Aviva Ventures provides early stage investment to back entrepreneurs with high growth businesses and, over time, expects to have a portfolio of small investments in a number of companies which have significant...
More on PMI
Ian Sawyer: The consequences of cancelling policies
Amid COVID-19
WPA extends remote GP service
COVID-19 letter sent to policyholders
Drewberry: Reduce pressure on the NHS
During COVID-19
ExCeL Centre to be used as hospital during COVID-19 crisis
Early next week
AMII: Health insurers must adapt following NHS deal
With payment holidays and enhanced NHS cash benefits
